BLUE Live signals | Maximize Profits with Getagraph.com

SELL 103544 min ago

@ $1.019

Issued: 14 Feb 2024 @ 09:30

Return: -10.43%

Previous signal: Feb 12 - 12:12

Previous signal: Buy

Return: -3.90 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	5.71M
Average Volume	8.40M
Market Cap	175.88M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.470 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.450
ATR14	$0.00100 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Colvin Richard A	Buy	199 000	Stock Option (right to buy)
2024-03-01	Colvin Richard A	Sell	6 770	Common Stock
2024-03-01	Vittiglio Joseph	Buy	199 000	Stock Option (right to buy)
2024-03-01	Obenshain Andrew	Buy	650 000	Stock Option (right to buy)
2024-03-04	Obenshain Andrew	Sell	6 095	Common Stock

INSIDER POWER
92.19
Last 95 transactions
Buy: 3 237 593 \| Sell: 214 711

Volume Correlation

Long: 0.14 (neutral)

Short: 0.77 (moderate)

Signal:(50.603) Neutral

bluebird bio Inc Correlation

10 Most Positive Correlations
ALXO	0.973
YJ	0.949
ORPH	0.947
CSSEP	0.946
PMVP	0.946
KNSA	0.945
GOOD	0.944
NAKD	0.944
IPA	0.943
EVLO	0.943

10 Most Negative Correlations
CPAQ	-0.961
MCAA	-0.958
SCOB	-0.957
LGACU	-0.957
ABGI	-0.957
FICV	-0.957
AGGR	-0.957
LGAC	-0.957
LVRA	-0.955
KAII	-0.955

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

bluebird bio Inc Correlation - Currency/Commodity

0.00
( neutral )

0.31
( neutral )

bluebird bio Inc Financials

Annual	2022
Revenue:	$3.60M
Gross Profit:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2022
Revenue:	$3.60M
Gross Profit:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2021
Revenue:	$3.66M
Gross Profit:	$-35.20M (-961.09 %)
EPS:	$-11.89

FY	2020
Revenue:	$250.73M
Gross Profit:	$245.34M (97.85 %)
EPS:	$-9.95

Financial Reports:

No articles found.

bluebird bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.